GlassScriptPhysician profile
Malik N Baz
NPI 1114923307
$1,556.25
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $634 · 2021: $13.10 · 2022: $161 · 2023: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.46 | 2019-2023 | Farxiga |
| Octapharma USA, INC. | $223.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $192.89 | 2019-2022 | |
| Csl Behring | $154.57 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $138.32 | 2019 | |
| Jazz Pharmaceuticals INC. | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.08 | 2020-2023 | Takhzyro |
| Shire North American Group INC | $92.16 | 2019 | |
| Incyte Corporation | $55.12 | 2023 | Opzelura |
| Greer Laboratories, INC. | $42.37 | 2022 | |
| Genentech USA, INC. | $36.76 | 2019 | |
| Pharming Healthcare, INC. | $23.04 | 2022 | |
| Biocryst US Sales Co., LLC | $21.25 | 2022 | |
| Genzyme Corporation | $20.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.96 | 2019 | |
| Covis Pharma Gmbh | $17.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malik Baz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.